Effect of Omega-3 Index on Cellular Metabolism and Quality of Life
NCT ID: NCT03159507
Last Updated: 2019-04-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
16 participants
INTERVENTIONAL
2017-10-02
2019-03-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of 2.0g Daily of MAG-EPA on the AA/EPA Ratio and Inflammation Biomarkers in a Healthy Population Aged of 50+.
NCT04897893
Influence of an Omega-3 SPM Supplement on Quality of Life
NCT02683850
An Evaluation of Omega-3 Fatty Acid
NCT03017651
Comparative Study of Three Different Formulations of Omega-3 (EPA+DHA)
NCT04159532
Intake of Omega 3 in Morbidly Obese Patients
NCT02113696
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MAG-EPA
MAG-EPA softgel (500mg), daily dose between 1g and 3.5g
MAG-EPA
Based on the result of the participant's Omega-3 index obtained from the blood sampling of visit 1, the daily dose of MAG-EPA will be adjusted to obtain an Omega-3 Index of 8.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MAG-EPA
Based on the result of the participant's Omega-3 index obtained from the blood sampling of visit 1, the daily dose of MAG-EPA will be adjusted to obtain an Omega-3 Index of 8.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Available for the entire duration of the study and willing to participate on the basis of the information provided in the FIU duly read and signed.
Exclusion Criteria
* Pregnant women who breast-feed or test positive for pregnancy
19 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Université du Québec à Rimouski
UNKNOWN
SCF Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anne-Julie Landry, MSc
Role: STUDY_DIRECTOR
SCF Pharma
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SCF Pharma
Rimouski, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IO3-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.